These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21947832)

  • 1. Cancer, diabetes, and angiotensin blockade: a question of hypohydration.
    Thornton SN
    J Clin Oncol; 2011 Nov; 29(33):4465-6. PubMed ID: 21947832
    [No Abstract]   [Full Text] [Related]  

  • 2. Are large sample size studies the answer to evaluate effects of drug use in non-clinical trial settings?
    Yang X; Chan JC
    J Clin Oncol; 2011 Nov; 29(33):4464-5; author reply 4466. PubMed ID: 21947826
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
    Chang CH; Lin JW; Wu LC; Lai MS
    J Clin Oncol; 2011 Aug; 29(22):3001-7. PubMed ID: 21690476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes and risk of cancer.
    Satija A; Spiegelman D; Giovannucci E; Hu FB
    BMJ; 2015 Jan; 350():g7707. PubMed ID: 25555822
    [No Abstract]   [Full Text] [Related]  

  • 5. Authors' reply to editorial linked to their umbrella review of meta-analyses of observational studies on type 2 diabetes and cancer.
    Tsilidis KK; Ioannidis JP
    BMJ; 2015 Feb; 350():h711. PubMed ID: 25673332
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.
    Mathur G; Noronha B; Rodrigues E; Davis G
    Diabetes Obes Metab; 2007 Sep; 9(5):617-29. PubMed ID: 17697055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
    Kimura G
    Clin Exp Nephrol; 2006 Sep; 10(3):226-7. PubMed ID: 17009082
    [No Abstract]   [Full Text] [Related]  

  • 8. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
    Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
    Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
    Kintscher U; Unger T
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiology of diabetes and cancer.
    Carstensen B; Jørgensen ME; Friis S
    Curr Diab Rep; 2014 Oct; 14(10):535. PubMed ID: 25156543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.
    Nomura M; Nishii H; Ozaki Y; Fujimoto N; Matsumoto T
    Physiol Behav; 2007 Jun; 91(2-3):223-8. PubMed ID: 17434545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.
    Lewis EJ;
    BMJ; 2005 May; 330(7502):1269-70; author reply 1270-1. PubMed ID: 15920133
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes complications and the renin-angiotensin system.
    Perkins BA; Aiello LP; Krolewski AS
    N Engl J Med; 2009 Jul; 361(1):83-5. PubMed ID: 19571288
    [No Abstract]   [Full Text] [Related]  

  • 18. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 20. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies.
    Tsilidis KK; Kasimis JC; Lopez DS; Ntzani EE; Ioannidis JP
    BMJ; 2015 Jan; 350():g7607. PubMed ID: 25555821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.